Saturday, June 15, 2024

SLB and Aker Carbon Capture Announce Closing of Carbon Capture Joint Venture

 The joint venture will enable wider adoption of market-ready and new carbon capture technologies for power and hard-to-abate industrial sectors worldwide


(BUSINESS WIRE) -- Regulatory News:


SLB (NYSE: SLB) and Aker Carbon Capture (ACC) announced today the closing of their previously announced joint venture. The new company combines technology portfolios, expertise and operations platforms to support accelerated carbon capture adoption for industrial decarbonization at scale.


“There is no credible pathway toward net zero without deploying carbon capture and sequestration (CCS) at scale,” said Gavin Rennick, president of SLB’s New Energy business. “In the next few decades, many industries that are crucial to our modern world must rapidly adopt CCS to decarbonize. Through the joint venture, we are excited to accelerate disruptive carbon capture technologies globally.”


The new company will combine ACC’s amine-based Advanced Carbon Capture™ technologies, including Just Catch™ and Big Catch™ modular plant technologies for medium- and large-scale facilities, and Just Catch Offshore™ for offshore gas turbines, with SLB’s portfolio of technology solutions, including non-aqueous solvent and emerging sorbent-based offerings. The company currently has seven technology installations in progress that have the capacity to capture up to 1 million tonnes of CO2 emissions per year.


“There is no business as usual in the push toward net zero—we will accelerate decarbonization today and commercialize innovative technologies for the future,” said Egil Fagerland, newly appointed Chief Executive Officer of the SLB–Aker Carbon Capture joint venture. “We are proud of the carbon capture plants we are delivering across various industries, with each customer being an important front-runner in its segment. Successful project deliveries are paving the way for other emitters to follow,” continued Fagerland.


The new company will be headquartered in Oslo. SLB owns 80% of the new company while ACC ASA owns the remaining 20% stake.


About SLB


SLB (NYSE: SLB) is a global technology company that drives energy innovation for a balanced planet. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.


About Aker Carbon Capture


Aker Carbon Capture is a pure-play carbon capture company with solutions, services and technologies serving a range of industries with carbon emissions, including the cement, bio and waste-to-energy, gas-to-power and blue hydrogen segments. Aker Carbon Capture's proprietary, carbon-capture technology offers a unique, environmentally friendly solution for removing CO2 emissions. Find out more at akercarboncapture.com.


Cautionary Statement Regarding Forward-Looking Statements:


This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240613961855/en/



Permalink

https://www.aetoswire.com/en/news/1406202439959

Contacts

Media

Moira Duff – Director of External Communications

SLB

Tel: +1 (713) 375-3407

media@slb.com


Stian Andreassen – ACC ASA media contact

Tel: +47 416 43 107

stian.andreassen@akerhorizons.com


Hanne Rolén – JV media contact

Tel: +47 990 02 571

hanne.rolen@akercarboncapture.com


Investors

James R. McDonald – Vice President of Investor Relations

Joy V. Domingo – Director of Investor Relations

SLB

Tel: +1 (713) 375-3535

investor-relations@slb.com


David Phillips, Head of Capital Markets

ACC

Tel: +44 7710 568279

david.phillips@akercarboncapture.com


 

Friday, June 14, 2024

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

 OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 14. June 2024 AETOSWire 


− Takeda to Receive Exclusive Option to License Global Rights to Olverembatinib in All Territories Outside of Mainland China, Hong Kong, Macau, Taiwan and Russia


− Olverembatinib Has the Potential to Address Significant Unmet Need for Patients with Chronic Myeloid Leukemia Following Treatment with Currently Approved TKIs


− Ascentage Pharma to Advance Late-Stage Clinical Development of Olverembatinib Prior to Potential Exercise of the Option to License


 


(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia.


Despite the impact TKIs have had in the treatment of patients with CML, there remains significant unmet need for patients whose disease is resistant or refractory to these therapies or who develop hard-to-treat mutations following these treatments.


“Takeda has a long history of driving important treatment advances for patients, particularly those with hematological cancers facing treatment gaps,” said Teresa Bitetti, president of the Global Oncology Business Unit at Takeda. “We are highly encouraged by the promising results olverembatinib has shown in the clinic to date and excited to have the opportunity to potentially further develop and deliver it to patients with chronic myeloid leukemia and other hematological cancers. This agreement aligns with our goal to support the advancement of both internal and external innovation to best serve patients.”


As part of the agreement, Ascentage Pharma will continue to be solely responsible for all clinical development of olverembatinib prior to potential exercise of the option to license. Olverembatinib is currently approved and marketed in China for the treatment of adult patients with TKI-resistant chronic-phase CML (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation and in adult patients with CP-CML resistant to and/or intolerant of first- and second-generation TKIs.


"We are thrilled to enter into this agreement with Takeda, which would allow us to leverage the global commercial expertise of an organization with a proven track record and global oncology footprint to potentially broaden the impact olverembatinib could have on patients in need around the world,” said Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma. “We have seen the impact olverembatinib has had on patients with CML in China and look forward to progressing development of olverembatinib in POLARIS-2, the global registrational Phase 3 study in previously treated adult patients with CP-CML with or without the T315I mutation.”


Under the terms of this agreement, Ascentage Pharma will receive an option payment of $100 million upon signing of the exclusive option to license agreement and will be eligible for an option exercise fee and additional potential milestone and royalty payments if Takeda exercises the option to license olverembatinib, with the exercise of the option being subject to customary regulatory approvals. Additionally, Ascentage Pharma will receive a minority equity investment from Takeda.


About Olverembatinib


Olverembatinib is an oral, third-generation BCR-ABL tyrosine kinase inhibitor (TKI). Olverembatinib is currently approved and marketed in China for the treatment of adult patients with TKI-resistant chronic-phase chronic myeloid leukemia (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation and in adult patients with CP-CML resistant to and/or intolerant of first- and second-generation TKIs. Ascentage Pharma is investigating olverembatinib in multiple clinical studies in several types of cancer. Olverembatinib has been granted orphan drug designation and Fast Track designation by the U.S. Food and Drug Administration (FDA) and orphan designation by the European Medicines Agency (EMA).


About Takeda


Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice


For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Forward-Looking Statements


This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Medical Information


This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240614852542/en/



Permalink

https://www.aetoswire.com/en/news/1406202439961

Contacts

Media:

Japanese Media

Jun Saito

jun.saito@takeda.com


U.S. and International Media

Jennifer Anderson

jennifer.anderson@takeda.com

Argonne and a Moroccan University Sign Agreement to Advance Green Energy Tech and Computing

 


LEMONT, Ill. - 

(BUSINESS WIRE) -- The U.S. Department of Energy’s (DOE) Argonne National Laboratory and University Mohammed VI Polytechnic (UM6P) have signed a memorandum of understanding (MOU) to collaborate on key areas of mutual interest related to green energy technology and the nexus of water and energy. In a ceremony held at UM6P’s campus in Benguerir, the MOU was signed by Argonne Laboratory Director Paul Kearns and UM6P President Hicham El Habti.


“We are excited to see what discoveries and innovations will result from our ongoing partnership,” said Kearns. ​“By working together, we’ll open new scientific frontiers for both our countries’ futures.”


“Today marks a significant milestone in our journey towards sustainable innovation. The signing of this Memorandum of Understanding with Argonne National Laboratory underscores our commitment to advancing research and development in renewable energy, energy grids, and water management. Together, we aim to leverage our collective expertise to create transformative solutions that will benefit not only our communities but also the global society,” said Hicham El Habti.


During a five-year period, the institutions will exchange published scientific and technical information, publications and reports. They will also organize meetings and cooperative activities to discuss technical topics. Additionally, the MOU includes the exchange of scientists, engineers and other specialists to participate in meetings and working sessions organized by the institutions, and to plan potential projects.


The institutions’ focus on green energy technology will include both energy storage and renewable energy. With respect to energy storage, advanced battery research is vital to achieving the International Energy Agency’s goal of reaching net zero emissions by 2050. Electric vehicles are a key part of this effort, and Morocco’s raw phosphoric acid materials hold great promise in the development of efficient lithium iron phosphate cathodes.


Green energy technology also encompasses renewable energy, including clean hydrogen. Last year, Argonne joined the Midwest Alliance for Clean Hydrogen. Known as MachH2, the alliance brings together 70 organizations to build the basis for a new, clean hydrogen economy. Argonne will share its discoveries with UM6P to expand the use of renewable energy in both the United States and Morocco.


Finally, the MOU will help advance research on clean water, which is a particularly pressing concern in Morocco. Argonne is leveraging its robust water research portfolio to tackle this issue. The portfolio includes material discovery and scaling-up for clean water innovations, new treatment and sustainability systems, and machine learning to combat water contamination.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240613503738/en/



Permalink

https://www.aetoswire.com/en/news/1406202439966

Contacts

Christopher J. Kramer

Head of Media Relations

Argonne National Laboratory

Office: 630.252.5580

Email: media@anl.gov

MultiBank Group Recognized as Top BaFin-Regulated Forex Broker

DUBAI, United Arab Emirates - Friday, 14. June 2024


(BUSINESS WIRE) -- MultiBank Group is thrilled to announce its recognition as a top BaFin-regulated forex broker by FXEmpire, a leading financial markets authority. This prestigious accolade highlights MultiBank Group's unwavering commitment to excellence, security, and innovation in the forex trading industry.


About BaFin: Regulating German Financial Markets


BaFin, Germany's Federal Financial Supervisory Authority, oversees the country's banking, securities, and insurance sectors. It ensures fair and transparent operations in the forex and CFD markets by enforcing rigorous standards.


Selection Methodology


FXEmpire's methodology for selecting the best BaFin-regulated brokers includes:


Regulation Verification: Ensuring each broker is BaFin-regulated, providing traders with high-level protection.


Cost Efficiency: Brokers offering low fees, including spreads, commissions, swaps, and non-trading fees.


User-Friendly Platforms: Emphasis on brokers with intuitive and feature-rich trading platforms.


Localization Options: Brokers that offer EUR as a base currency, local offices, and German-language customer support.


FXEmpire's team of experts, with extensive hands-on forex trading experience, meticulously examined and analyzed each broker's strengths and weaknesses to select the best BaFin-regulated forex brokers across various categories.


MultiBank Group's Excellence in Forex Trading


MultiBank Group's recognition as a top BaFin-regulated forex broker underscores its dedication to providing traders with superior services and robust security measures. The Group's innovative trading solutions, including its all-in-one user-friendly app, are setting new benchmarks in the industry. MultiBank Group strives for outstanding service, ensuring its clients have access to the best trading experience possible.


Looking Forward


MultiBank Group remains committed to pushing the boundaries of what is possible in the forex trading world. The Group is constantly exploring new technologies and strategies to further enhance its offerings, ensuring that traders always have access to the most advanced and secure trading tools available. This recognition by FXEmpire is a testament to the Group's relentless pursuit of excellence and unwavering dedication to its clients' success.


ABOUT MULTIBANK GROUP


Founded in California, USA, in 2005, MultiBank Group has grown to command a daily trading volume exceeding $12.1 billion, serving over 1 million customers. MultiBank Group has matured into one of the largest online financial derivatives providers globally, offering an array of brokerage services and asset management solutions. The group’s award-winning trading platforms offer up to 500:1 leverage on a diverse range of products, including Forex, Metals, Shares, Commodities, Indices, and Digital Assets. For more information, visit https://multibankfx.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240614306878/en/



Permalink

https://www.aetoswire.com/en/news/1406202439963

Contacts

faouz.rejeb@multibank.io

Manhattan Associates Named a Leader in Gartner® Magic Quadrant™ for WMS for the Sixteenth Consecutive Time

  (BUSINESS WIRE) -- Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, today announced that it has been named a Leader in Gartner® Magic Quadrant™ for Warehouse Management Systems1 for the 16th time in a row. Manhattan has been a Leader in every Gartner WMS Magic Quadrant since the report’s inception in 2006.

Manhattan Active® Warehouse Management is cloud-native and built on a microservices architecture to meet the challenges of today and tomorrow. This advanced infrastructure, with its scalability and ease-of-use, makes Manhattan Active WM well suited for warehouses with medium levels of complexity to the world’s largest, most automated distribution centers.

It advances operations beyond basic picking, packing, and shipping to create and flawlessly execute a hyper-flow of goods and information. Also, Manhattan’s Labor Management is infused with behavioral science and gamification to create more compelling and rewarding experiences for warehouse associates.

“We are thrilled to be named a Magic Quadrant Leader in Warehouse Management Systems by Gartner once again,” said Adam Kline, senior director of Product Management for Manhattan Associates. “We believe, this reflects our industry-leading, continuous innovation and commitment to unifying every aspect of the supply chain.”

Manhattan is a trailblazer in unifying warehouse, labor management, automation, transportation and yard management into a comprehensive supply chain execution solution. This unification unlocks optimization opportunities like never before, and that are impossible with siloed offerings.

Backed by the industry’s most-experienced services and support teams, and a large ecosystem of global partners, Manhattan Active Warehouse Management comes with Yard Management and is a game-changer for any company operating in fast-moving and demanding environments.

Additionally, the company eases implementation for its customers with Manhattan ProActive, a low code application platform for developers specifically designed to visually extend solutions built on Manhattan Active® platform technology.

To download a complimentary copy of the Gartner WMS Magic Quadrant, click HERE.

Receive up-to-date product, customer, and partner news directly from Manhattan Associates on LinkedInTwitter, and Facebook.

Gartner Disclaimer:

GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Manhattan Associates:

Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers. Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.

1 Gartner, Magic Quadrant for Warehouse Management Systems, Simon Tunstall, Dwight Klappich, Rishabh Narang, Federica Stufano 8 May 2024.

 



Contacts

Press:
James Canham-Ash
Manhattan Associates
jash@manh.com


Brightcove to Power FrightPix, a New Streaming Destination for Horror, Thriller and True Crime Fans

 Brightcove’s platform will allow FrightPix to manage, distribute, and monetize its content to meet the needs of horror content fans everywhere

(BUSINESS WIRE) -- Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced it is welcoming FrightPix – the new, free, ad-supported video-on-demand service (AVOD) for all things horror, thriller, and true crime – to its roster of media customers. Launching June 15, 2024, FrightPix will rely on Brightcove’s award-winning platform to distribute its content to audiences across the U.S., delivering an unparalleled viewer experience through its advanced streaming technology.

FrightPix will blend classic scares, modern thrillers, true crime tales, and FrightPix Originals into a convenient and free service for fans. By leveraging Brightcove’s reliable and scalable video technology, FrightPix will provide a seamless, curated, high-quality viewing experience across any device for its audience.

“As the streaming market evolves, viewers are demonstrating a clear desire for more tailored experiences. At Brightcove, we deeply believe regional, targeted-audience and genre-focused streaming services have enormous opportunities to be successful by delivering unique viewing experiences serving their specific audience’s needs,” said Marc DeBevoise, CEO of Brightcove. “We are committed to transforming the way consumers experience content, and as the backbone technology for FrightPix, we’re supporting them in taking the lead in delivering horror fans an incredible entertainment experience and destination."

As the demand for specialized content platforms surges, independent media companies require experienced partners that can successfully operate their tech stacks cost-effectively without impacting the user experience. In evaluating reliability and innovation, FrightPix chose Brightcove’s video-cloud streaming platform for its industry-leading advantages, including unparalleled video quality, global scalability, unmatched customer support, and robust analytics designed to understand viewer preferences and behavior and create actionable insights to optimize content and advertising strategies for maximum monetization.

"As we launch this month, partnering with Brightcove will allow FrightPix to become the premier streaming destination for horror, thriller, and true crime enthusiasts," said Eric Tomosunas, CEO of FrightPix. "With Brightcove’s industry-leading streaming technology, our 'FrightFans' will have the opportunity to enjoy the most spine-tingling movies and series with exceptional reliability and quality. This collaboration is a pivotal step in our platform's ability to deliver top-tier genre entertainment for free, and we are grateful to be part of the Brightcove family."

FrightPix joins a roster of media companies that rely on Brightcove to power their streaming capabilities, including The Academy of Motion Picture Arts and Sciences, Acun Medya, AMC Networks, BBC Studios, Canela Media, J.COM, MotoAmerica, REELZ, SBT TV, and SKY Mexico.

For more information, visit Brightcove.com.

About FrightPix
FrightPix, launching June 15, 2024, is the only streaming destination for all things horror, thriller, and true crime for free. FrightFans get to feast upon the most spine-tingling movies and series ever amassed in one streaming platform and FrightPix is available to download on Apple TV, Amazon Fire TV, Roku TV as well as iOS and Android devices. You can also stream and find more information at www.frightpix.com.

About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedInXFacebookInstagramThreads, and YouTube. Visit Brightcove.com.

 



Contacts

Media Contacts
Brightcove
Joseph J. Nuñez, Director of Communications & Public Relations
jnunez@brightcove.com

FrightPix
Kayla J. Williams, kj pr
kayla@kj-pr.co


Corona Cero Inspires Fans to Embrace Golden Moments


 SÃO PAULO -

Corona Cero’s Olympic Games debut captures the power of golden moments that exist in everyday lives

(BUSINESS WIRE) -- Today, Corona Cero, the global beer sponsor of the Olympic & Paralympic Games, introduced its "For Every Golden Moment" platform, celebrating the golden moments of the games and reminding the world to embrace and enjoy their own golden moments occurring in life. This marks the launch of the no-alcohol brand’s inaugural Olympic Games activation since AB InBev was announced as the first beer sponsor at the Worldwide Olympic Partner level.


“Offering this award-winning no-alcohol beer brings more choice to fans around the world,” said Marcel Marcondes, AB InBev Global Chief Marketing Officer. “Corona Cero is a perfect fit for this global occasion, and further reinforces our brand’s commitment to moderation, relaxation, and celebration.”


The Corona brand invites the world to get outside and reconnect with nature – a theme that brings a fresh perspective of relaxation and celebration to the Olympic Games. In reminding the world to unwind, stay close to nature and celebrate life’s moments big and small, Corona Cero brings people together around golden moments. From breaking records to taking in beautiful sunsets, reminding the world the power these meaningful moments bring to daily life.


Corona Cero is launching the platform in 40+ markets globally and bringing it to life across all media touchpoints, from films, social media, OOH, experiences and trade, including Olympics-themed bottles in select markets worldwide. The campaign captures the emotion of celebratory golden moments from Olympians and more, drawing parallels from real Olympic golden moments from Rio 2016 and Tokyo 2020 and creating analogies of golden moments that can be experienced by all.


“As the first-ever global beer sponsor of the Olympic Games, Corona Cero, with its 'For Every Golden Moment' campaign, offers a fresh perspective on celebration for fans and athletes around the world,” said Anne-Sophie Voumard, Managing Director, International Olympic Committee Television and Marketing Services. “Together, we strive to promote sports and moderation, contributing to a better world."


Corona Cero is served in the brand’s signature flint bottle and to elevate the experience, consumers of legal drinking age around the world can enjoy Corona’s famous lime ritual, a key differentiator unique to the brand.


With centuries of brewing history, AB InBev has seen countless new friendships, connections, and experiences built on a shared love of sport and beer. Sport is a strong force for positive change, and AB InBev brands are pleased to be a part of that legacy with decades of historic, award-winning and responsible sports marketing.


The brand partnered with a curated global team at creative agency, Grey, to develop the platform idea, brought to life by Academy Award-nominated and Emmy Award-winning director, Henry-Alex Rubin, as well as its top creative partners from across the globe.


To view the film, visit Corona’s YouTube channel.


About Corona Global

Corona, an AB InBev global brand*, is the iconic beer brand that is synonymous with paradise with a presence in 180 countries. Recognized as the world’s most valuable beer brand in Kantar’s BrandZ global 2024 rankings, Corona invites the world outside, beckoning you to reconnect with your essential nature and embrace the simple pleasures of life. But it's not just about the beer – it's about the ritual. The ritual of adding a slice of lime to your Corona, an experience that elevates the moment. Corona isn't just a beverage; it's nature in a bottle. And we strive to help protect nature and have become the first global beverage brand with a net-zero plastic footprint. This builds on our longstanding ambition to help protect the world’s oceans and beaches from plastic pollution. Every sip of Corona is a celebration of nature and the beauty of the world around us.


*Corona is not sold by AB InBev in the United States.


About The International Olympic Committee

The International Olympic Committee is a not-for-profit independent international organisation made up of volunteers, which is committed to building a better world through sport. It redistributes more than 90 per cent of its income to the wider sporting movement, which means that every day the equivalent of USD 4.25 million goes to help athletes and sports organisations at all levels around the world.


About AB InBev

AB InBev is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Our diverse portfolio of well over 500 beer brands includes global brands Budweiser®, Corona®, Stella Artois® and Michelob Ultra®; multi-country brands Beck’s®, Hoegaarden® and Leffe®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 155,000 colleagues based in nearly 50 countries worldwide. For 2023, AB InBev’s reported revenue was 59.4 billion USD (excluding JVs and associates).


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240613074831/en/



Permalink

https://www.aetoswire.com/en/news/1306202439941

Contacts

AB InBev Media Relations

E-mail: media.relations@ab-inbev.com